The Signature of Serum Modified Nucleosides in Uveitis
Investigative Ophthalmology & Visual Science · 2025
DOI: 10.1167/iovs.66.2.68 ↗At a glance
Journal article in Investigative Ophthalmology & Visual Science, 2025. Written by Haoze Zhou and 7 co-authors. Institution: Eye Center, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China. Major MEDLINE topics: Uveitis, Nucleosides. Cited 3 times so far (Crossref); 67 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Purpose
This study aims to evaluate the metabolism of serum-modified nucleosides in uveitis by using liquid chromatography-tandem mass spectrometry (LC-MS) and to develop potential diagnostic biomarkers for uveitis.
Methods
Forty-two patients with different subtypes of uveitis (idiopathic uveitis, Vogt-Koyanagi-Harada [VKH] disease, and ankylosing spondylitis [AS]) and 32 healthy controls were recruited in this retrospective case-control study. The concentrations of 23 modified nucleosides in patient serum were quantified by LC-MS. The data was statistically analyzed with SPSS and GraphPad Prism.
Results
The data revealed that 13 out of 23 modified nucleosides (m6A, m1A, m6Am, Cm, ac4C, Gm, m1G, m2G, m2,2G, Um, m3U, m5U, and m5Um) effectively showed quantifiable chromatographic peaks. The statistical results indicated that there were extremely significant differences for m2G, Gm, Cm, and m1G between healthy controls and uveitis patients. The differences for Gm, m6A,and m5U were able to further assort idiopathic uveitis and uveitis with systemic inflammation including VKH and AS. Interestingly, each specific subtype of uveitis is characterized by its signature combination of serum-modified nucleotides comparing with healthy controls.
Conclusions
This study revealed that the metabolism of serum-modified nucleosides in uveitis patients display significant differences from healthy controls. The signature combination of serum modified nucleotides for each subtype of uveitis may be applied for the potential diagnosis of uveitis.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Eye Center, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
- Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
- Institute of Genetics, Zhejiang University International School of Medicine, Hangzhou, China.
Cite
APA
Zhou, H., Hu, Y., Qin, G., Kong, J., Hong, X., Guo, C., Zou, J., & Feng, L. (2025). The Signature of Serum Modified Nucleosides in Uveitis. Investigative Ophthalmology & Visual Science. https://doi.org/10.1167/iovs.66.2.68
Vancouver
Zhou H, Hu Y, Qin G, Kong J, Hong X, Guo C, et al. The Signature of Serum Modified Nucleosides in Uveitis. Investigative Ophthalmology & Visual Science. 2025. doi:10.1167/iovs.66.2.68
BibTeX
@article{Zhou2025,
author = {Zhou, Haoze and Hu, Yiqiu and Qin, Guangming and Kong, Jinfeng and Hong, Xiujuan and Guo, Cheng and Zou, Jian and Feng, Lei},
title = {The Signature of Serum Modified Nucleosides in Uveitis},
journal = {Investigative Ophthalmology & Visual Science},
year = {2025},
doi = {10.1167/iovs.66.2.68}
}
EUVIMED